MICROSAIC SYSTEMS PLC

Investor Presentation • Sep 13, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5496Q

Microsaic Systems plc

13 September 2017

13 September 2017

Microsaic Systems plc

("Microsaic", "Microsaic Systems" or the "Company")

Microsaic to Exhibit at BioProcess International, Boston

Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry ("MS") instruments will be exhibiting at BioProcess International ("BPI"), September 25-28 2017, at booth 200 at the Hynes Convention Centre, Boston, MA, USA.

BPI is the largest bioprocessing event in the world, bringing together the biggest global names in bioprocessing science and technology that are focused on accelerating promising biologics to market.

Bioprocessing is an essential process for producing and purifying intact and functional biological material from cells. Microsaic's strategy is to work with the key providers of bioprocessing equipment, in particular those companies involved in biologic purification, to apply its MS instrument (the 4000 MiD®) for the detection of therapeutic proteins and antibodies.

The benefits of Microsaic's point-of-use MS technology, in combination with its patented innovation for on-line desalting, make it a powerful on-line and at-line confirmatory analysis tool with multiple points of entry in upstream and downstream bioprocessing. This enables important time and cost savings of making the biologics, as analysis times can be reduced from days or even weeks to minutes.

MS is a powerful technique which allows the effective implementation of "QbD" (Quality by Design), a key industry and regulatory driver for current and future production of biologics.

Glenn Tracey, Microsaic's Chief Operating Officer, commented:

"We see significant opportunities for Microsaic's MiD instruments integrated into multiple areas of bioprocessing, to enhance efficiency and quality. Bioprocessing is a rapidly growing market, as indicated by the growth in biologics; 8 of the top 10 drugs sold in 2015 were biologics with multibillion dollar annual sales and their market share, in terms of drugs in development and on the market, continues to grow. Our aim is to develop partnerships with key providers of bioprocessing equipment in this increasingly profitable area that has a strong market-pull for MS."

Enquiries:
Microsaic Systems plc Glenn Tracey, COO Bevan Metcalf, FD	+44 (0) 1483 751577
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson Liz Yong	+44 (0)20 7496 3000
Citigate Dewe Rogerson (Financial PR) Mark Swallow Shabnam Bashir	+44 (0)20 7638 9571

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

Microsaic's core product, the 4000 MiD®, is one of the smallest MS systems in the world, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAZLLFFDKFEBBD